{
    "id": 3858,
    "fullName": "PIK3CA N345K",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "PIK3CA N345K lies within the C2 PI3K-type domain of the Pik3ca protein (UniProt.org). N345K results in increased phosphorylation of Akt, activation of downstream signaling, and is transforming in cell culture (PMID: 17376864, PMID: 29533785).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 101,
                    "pubMedId": 17376864,
                    "title": "Rare cancer-specific mutations in PIK3CA show gain of function.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17376864"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5290,
        "geneSymbol": "PIK3CA",
        "terms": [
            "PIK3CA",
            "CLAPO",
            "CLOVE",
            "CWS5",
            "MCAP",
            "MCM",
            "MCMTC",
            "p110-alpha",
            "PI3K",
            "PI3K-alpha"
        ]
    },
    "variant": "N345K",
    "createDate": "03/18/2015",
    "updateDate": "10/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 172017,
        "transcript": "NM_006218",
        "gDna": "chr3:g.179203765T>G",
        "cDna": "c.1035T>G",
        "protein": "p.N345K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4245,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tykerb (lapatinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4231,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alpelisib (BYL719) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4259,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4224,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20216,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (NRG-GY008) trial, Aliqopa (copanlisib) was well tolerated but demonstrated limited efficacy, resulted in stable disease in a patient with endometrial mixed adenocarcinoma harboring PIK3CA N345K (PMID: 31934607).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 995,
                "therapyName": "Copanlisib",
                "synonyms": null
            },
            "indication": {
                "id": 7664,
                "name": "endometrial mixed adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17733,
                    "pubMedId": 31934607,
                    "title": "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31934607"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 4262,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited survival of transformed cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17326,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I (SWOG S1400B) trial, Taselisib (GDC-0032) treatment did not meet primary endpoint in patients with lung squamous cell carcinoma harboring PIK3CA mutations, none of the 2 patients harboring PIK3CA N345K demonstrated response (PMID: 31158500; NCT02785913).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15376,
                    "pubMedId": 31158500,
                    "title": "SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31158500"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4238,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4252,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) inhibited survival of transformed breast epithelial cell lines overexpressing PIK3CA N345K in culture (PMID: 26627007).",
            "molecularProfile": {
                "id": 3668,
                "profileName": "PIK3CA N345K"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4255,
                    "pubMedId": 26627007,
                    "title": "Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26627007"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2952,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CH5132799 inhibited proliferation of a breast cancer cell line harboring PIK3CA N345K and ERBB2 (HER2) amplification in culture (PMID: 21558396).",
            "molecularProfile": {
                "id": 10739,
                "profileName": "ERBB2 amp PIK3CA N345K"
            },
            "therapy": {
                "id": 2152,
                "therapyName": "CH5132799",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1985,
                    "pubMedId": 21558396,
                    "title": "The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21558396"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10236,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9496 reduced tumor growth in a breast cancer patient-derived xenograft (PDX) model harboring ESR1 D538G, which also harbored PIK3CA N345K, ARID1A E1776*, and ARID1A S705fs (PMID: 27986707).",
            "molecularProfile": {
                "id": 27322,
                "profileName": "ARID1A S705fs ARID1A E1776* ESR1 D538G PIK3CA N345K"
            },
            "therapy": {
                "id": 2997,
                "therapyName": "AZD9496",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8160,
                    "pubMedId": 27986707,
                    "title": "Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27986707"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3668,
            "profileName": "PIK3CA N345K",
            "profileTreatmentApproaches": [
                {
                    "id": 17294,
                    "name": "Akt Inhibitor (Pan)",
                    "profileName": "PIK3CA N345K"
                },
                {
                    "id": 17292,
                    "name": "PI3K Inhibitor (Pan)",
                    "profileName": "PIK3CA N345K"
                },
                {
                    "id": 17288,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "PIK3CA N345K"
                },
                {
                    "id": 17291,
                    "name": "Akt2 Inhibitor",
                    "profileName": "PIK3CA N345K"
                },
                {
                    "id": 17293,
                    "name": "Akt1 Inhibitor",
                    "profileName": "PIK3CA N345K"
                },
                {
                    "id": 17287,
                    "name": "mTOR Inhibitor",
                    "profileName": "PIK3CA N345K"
                },
                {
                    "id": 17290,
                    "name": "PIK3CA inhibitor",
                    "profileName": "PIK3CA N345K"
                },
                {
                    "id": 17289,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "PIK3CA N345K"
                }
            ]
        },
        {
            "id": 10739,
            "profileName": "ERBB2 amp PIK3CA N345K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27322,
            "profileName": "ARID1A S705fs ARID1A E1776* ESR1 D538G PIK3CA N345K",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 172016,
            "transcript": "XM_006713658",
            "gDna": "chr3:g.179203765T>G",
            "cDna": "c.1035T>G",
            "protein": "p.N345K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172018,
            "transcript": "XM_011512894",
            "gDna": "chr3:g.179203765T>G",
            "cDna": "c.1035T>G",
            "protein": "p.N345K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 172017,
            "transcript": "NM_006218",
            "gDna": "chr3:g.179203765T>G",
            "cDna": "c.1035T>G",
            "protein": "p.N345K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}